The biological response modifier r(I),,-r(C12-UQ),, referred to here as mismatched double-stranded (ds) RNA, was examined for anthuman immunodeficiency virus (HIV) activity in vitro because of its known antiviral activity and ability to induce interferon (IFN) in other biological systems [Carter, W. A., Strayer, D. R., Hubbell, H. R. & Brodsky, I. (1985) J. Biol. Response Modif. 4, 495-502]. We found that cultures of the highly HIV-permissive T-cell line C3 were afforded significant protection from HIV infection when incubated in growth media supplemented with mismatched dsRNA at 10-50 ,Lg/mi prior to virus challenge. Similar results were obtained at 50 ,ug of mismatched dsRNA per ml in cultures of the T-lymphoblastoid cell line CEM. Infections were monitored by indirect immunofluorescence ofcells for viral p24 antigen expression, reverse transcriptase activity in culture fluids for virus production, and vital dye uptake for cytopathic effect. Antiviral activity was increased by the continued presence of mismatched dsRNA in cultures following virus challenge. A one-time exposure to mismatched dsRNA (50 ,ug/mi) provided greater antiviral activity than either a one-time exposure to recombinant IFN-a [250 international units (W)/ml], IFN-(3 (250 IU/ml), or IFN-y (50 IU/ml) in cultures of CEM cells, or a one-time exposure to a combination of all three IFNs (150 IU each per ml) in cultures of C3 cells. Mismatched dsRNA at 50 ,Lg/ml had no effect on cell division, RNA and protein synthesis, or virus replication in all T-cell lines examined. A clear distinction between the activities of mismatched dsRNA and IFN was the ability ofIFN to suppress the in vitro replication of HIV that occurred at IFN concentrations (150 IU each of a, A3, and y per ml) that provided less antiviral activity than mismatched dsRNA (50 ,ug/ml). The results of these in vitro studies suggest a potential therapeutic value for mismatched dsRNA in the treatment of acquired immunodeficiency syndrome (AIODS).
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Human immunodeficiency virus (HIV), also known as human T-cell lymphotropic virus III (HTLV-III) or lymphadenopathyassociated virus (LAV), is a highly variable type D retrovirus recently identified as the etiologic agent of acquired immunodeficiency syndrome (AIDS) (1) (2) (3) . A distinguishing feature of the virus is its selective cytotoxicity for helper T lymphocytes (4) . Infection in vivo is manifested by severe and diverse aberrations of the immune system, primary among these being a decreased T-helper/T-suppressor cell ratio (5) . In addition, monocytes have been identified as secondary targets for HIV infection and may be responsible for the frequent encephalopathy associated with AIDS (6) . Other immune dysfunctions associated with AIDS, but of unknown relationship to direct virus infection, include impaired natural killer cell activity (7) (8) (9) , polyclonal B-cell activation (10, 11) , and a wide range of serological abnormalities (5) .
Lvirus replication)
The first generation, specific anti-AIDS chemotherapeutic agents have focused on inhibition of HIV replication with the anticipation that an effective drug would protect uninfected HIV target cells from a progressive destruction of the host immune system (12) . One such candidate for the treatment of AIDS is interferon (IFN). The three molecular forms of IFN (i.e., a, f3, and y) are well known for their antiviral, antineoplastic, and immunomodulatory activities (13, 14) . It is reasonable to hypothesize that the biological responses elicited by IFN in vivo could modulate the natural progression of AIDS by inhibiting HIV replication, suppressing AIDS-associated neoplasms, and facilitating the reconstitution of impaired immune functions. Initial evidence for the potential efficacy of IFN in the therapy of AIDS came from the finding that antiserum to human IFN-a facilitates the isolation of HIV from peripheral blood mononuclear cells (PBMCs) of AIDS patients in vitro (1) . Additional evidence came from the finding that recombinant IFN-aA can protect normal PBMCs from infection with HIV in vitro (15) . Recently, several other molecular forms of IFN-a and a preparation of IFN-f3 were also shown to inhibit the in vitro replication of HIV in PBMCs (16) . Double-stranded RNAs (dsRNAs) are inducers of the various molecular forms of IFN, activate certain IFNassociated intracellular mediators, possess immunomodulatory activities and inhibit tumor cell proliferation (17) (18) (19) (20) (21) (22) (23) (24) (25) . The therapeutic value of dsRNAs as antiviral/anticancer drugs was initially difficult to assess due to the toxicity of the prototype molecule r(I), r(C)Q (23, 26) . Later it was found that by introducing a mismatched, non-hydrogen-bonded base residue (uracil) into the polycytidylic acid polymer strand at every twelfth residue, the mismatched dsRNA polymer, r(I)n r(C12-U)n, was rendered sensitive to RNase destruction while retaining the one helical turn required for biological activity (27) . This mismatched analogue, commonly known as Ampligen, is much less toxic while retaining the therapeutic properties mentioned above (18) (19) (20) (21) (22) . These therapeutic properties, combined with a low-toxicity profile, make mismatched dsRNAs important candidates as potential anti-AIDS drugs. In the present study we have assessed this potential in vitro and found that mismatched dsRNA of the form r(I)n r(C12-U),, affords significant protection of T-cells from infection by two HIV isolates, HTLV-III and LAV.
MATERIALS AND METHODS Cell and Virus Stock Cultures. CEM/LAV (28) Following the preincubation period, the cultures were inoculated with 5 ml of clarified conditioned H9/HTLV-III or CEM/LAV culture fluid. Virus particles were allowed to adsorb for 5 hr at 360C, and unadsorbed particles were removed by two washes with 10 ml of RPMI 1640 medium. Cultures were then incubated in 20 ml of fresh growth medium with or without effectors as described. Cell densities were reduced, and media was replaced at given times to avoid overgrowth. Samples for indirect immunofluorescence (IIF), RT assays, cell counts, and neutral red staining were obtained at these times. IIF and RT assays were done as described (33, 34) .
Vital Dye Uptake. Cells were collected from suspension by low-speed centrifugation and resuspended in 5 ml of growth medium containing a 1:150 dilution of Finter 
RESULTS
Mismatched dsRNA and IFN Induced Protection of C3 Cells from HIV Infection. Fig. 1 Following this incubation the cultures were challenged with HTLV-III (2.6 x 106 cpm of RT activity) as described and further incubated in 20 ml of fresh effector-free growth medium for 7 days. Cell densities were proportionately reduced, and media were replaced on days 3 Fig. 3 compares the antiviral activities of mismatched dsRNA and IFN with respect to protection from the virus-induced lytic response in association with HIV p24 expression and virus production 7 days after virus (HTLV-III) challenge. Cell lysis was most apparent in the control (no effector) culture (67% cell reduction), which also contained the highest percent of cells expressing p24 (100%) and the greatest amount of RT activity in culture fluid (1163 x 103 cpm/ml). Pretreatment and continued incubation of cells with mismatched dsRNA (50 ,ug/ml) afforded the greatest protection (0% cell reduction) which was associated with a total absence of RT activity and less than 1% ofcells expressing p24. Protection was also observed if cultures were exposed to mismatched dsRNA (50 pg/ml) a single time immediately prior to virus challenge where a 10% reduction in cells was observed in association with 12% of 
DISCUSSION
In this report, we have demonstrated the ability of a mismatched dsRNA, r(I)n r(C12-U)n, to afford significant protection of T-cells from HIV infection in vitro. Antiviral activity was demonstrated in two T-cell lines, C3 and CEM, and against two HIV isolates, HTLV-III and LAV (Figs. 1-4 ). This antiviral activity was not attributed to an effect on cell division or RNA and protein synthesis (Table 1) .
Because dsRNAs are potent inducers of the various molecular forms of IFN (13, 17) , and because IFN has been shown here (Figs. [2] [3] [4] and elsewhere (15, 16) to possess anti-HIV activity in vitro, then IFN could at least in part be responsible for the anti-HIV activity of mismatched dsRNA. Evidence suggesting a mechanism for mismatched dsRNA distinct from IFN induction comes from our observation that mismatched dsRNA was a more potent anti-HIV agent than IFN-a, IFN-/3, or IFN-y alone, or all three IFNs combined, at doses (50-250 IU/ml) previously shown to be optimal for anti-HIV activity in vitro (15, 16) . Further evidence comes from our observation that treatment with an IFN-a3,',y mixture that provided less anti-HIV activity in uninfected cells than mismatched dsRNA (Figs. 2 and 3 ) also inhibited virus replication in cultures of CEM/LAV and H9/HTLV-III cells (Table 2) , whereas mismatched dsRNA had no effect on the replication of these viruses (Table 1) .
Variations in anti-HIV activities of different IFN preparations were evident from our studies which showed that IFN-y was active while IFN-,B was inactive against LAV in CEM cells (Fig. 4) , whereas the opposite was true for other preparations of these IFNs in PBMCs challenged with HTLV-III, LAV, and AIDS-associated retrovirus as reported elsewhere (16) . The apparent greater efficacy of mismatched dsRNA over IFN for protecting T-cells from HIV infection in vitro may be artifactual in the sense that mismatched dsRNA could have induced the natural IFN products of the target cells, these natural IFNs in turn being more potent than the IFN preparations added exogenously. Since dsRNA not only induces IFN biosynthesis, but activates certain IFN-induced enzymes (13, 24) , the greater efficacy of mismatched dsRNA in protecting target T-cells from HIV infection may be the direct result of enzyme activity dependent on dsRNA activation. One such mediator of IFN action could be the activity of (2'-5')oligoadenylate synthetase, an enzyme induced by IFN that synthesizes 2'-5' oligoadenylate molecules, which in turn function to activate a latent ribonuclease specific for single-stranded RNA (13, 14) . Thus, the amount of IFN induced by dsRNA, together with the IFNmediated pathway affected, may also explain the observed difference between IFN and mismatched dsRNA on the in vitro replication of HIV. For example, low levels of IFN induction concomitant with activation of a specific IFN-mediated process may be sufficient to exert antiviral activity in cells challenged with HIV, but insufficient to inhibit virus replication in cells already productively infected. Although not studied in this report, it is possible that exogenous IFNs in combination with mismatched dsRNA may result in greater inhibition of HIV production in cells already infected with HIV than with the IFNs alone.
The ability of mismatched dsRNA to protect target T-cells from HIV infection in vitro suggests that it may have potential efficacy in the treatment of AIDS. Since the activity of mismatched dsRNA demonstrated in this report is to protect uninfected cells, the efficacy of mismatched dsRNA as a single anti-HIV drug may be greater in ARC (AIDS related complex) patients than in end-stage AIDS. The higher levels of T-helper cells and the presence of functional natural killer cells in AIDS related complex patients suggest the presence of uninfected stem cell populations of these HIV target cells whose protection from HIV infection by mismatched dsRNA could theoretically result in the reconstitution of the abrogated immune functions associated with AIDS. In consideration of the current paucity of potential anti-HIV drugs with acceptable associated toxicities (12) , and on the basis of our in vitro data, mismatched dsRNA appears to be a major candidate drug for the treatment of AIDS related complex and possibly AIDS. Fortunately, the severe in vivo toxicities associated with the dsRNAs are not observed with the mismatched analogue, Ampligen (21, 22) . 
